Table 2.

Baseline characteristics of AIDS Patients with and without reported hypertension or use of hypertension treatment, as of December 31, 2011

		Reported HTN or Treatment
	Total (n=2390)	No (n=1860)	Yes (n=530)	P-value
Demographics
Age – y, Mean (SD)	43 (9)	42 (8)	48 (9)	<0.0001
Male, %	80	80	81	0.55
Black, %	37	34	46	<0.0001
College graduate, %	30	30	30	0.97
Insurance, %				<0.0001
Uninsured	16	18	10
Publically insured	53	51	61
Privately insured	31	32	29
Unemployed, %	13	13	12	0.83
Weight – kg, Mean (SD)	75 (15)	74 (14)	79 (16)	<0.0001
HIV Characteristics and Treatment
HIV Risk Factor, %*				0.27
MSM only	56	56	55
IDU only	9	9	9
MSM and IDU	4	4	5
Heterosexual	26	27	24
Time since AIDS diagnosis – y, Mean (SD)	4.9 (4.0)	4.6 (3.8)	6.0 (4.3)	<0.0001
CD4+ T-cells/µL, Median (pSD)	179 (205)	164 (200)	227 (233)	<0.0001
Nadir CD4+ T-cells/µL, Median (pSD)	30 (59)	27 (56)	34 (67)	0.02
Viral load – log copies/mL, Mean (SD)	3.2 (1.6)	3.2 (1.6)	3.0 (1.5)	0.0008
Peak viral load – log copies/mL, Mean (SD)	5.1 (1.0)	5.1 (0.9)	5.0 (1.1)	0.02
HAART use, %	84	83	86	0.10
PI-based HAART, %	63	63	61	0.46
NNRTI-based HAART, %	38	37	42	0.05
Comorbidities
CMV retinitis, %	21	22	17	0.01
Hyperlipidemia, %	20	16	34	<0.0001
Diabetes, %	9	6	18	<0.0001
Hepatitis C virus, %				0.03
Uninfected	79	80	74
Cleared	4	4	6
Chronic	17	16	20
Central Retinal Vasculature - µm, Mean, (SD)**	(n=1396)	(n=1103)	(n=293)
CRAE	148 (16)	149 (16)	143 (15)	<0.0001
CRVE	223 (25)	224 (25)	221 (25)	0.13

22% (95% CI 21–24%) of participants had hypertension at enrollment.

^*Percents do not add to 100; category of “other” not included.

^**n excludes participants with ocular opportunistic infections.

HTN: hypertension, MSM: men who have sex with men, IDU: injection drug use, HAART: highly-active antiretroviral therapy, PI: protease inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor, CMV: cytomegalovirus, CRAE: central retinal artery equivalent, CRVE: central retinal vein equivalent